BNP/PUT/ELI LILLY & CO/1000/0.1/19.12.25 | Real-time Boerse Frankfurt Warrants 02:51:09 27/06/2024 pm IST | ||
| 15.89 EUR | -1.30% |
|
| Current month | -21.31% | ||
| 1 month | -23.81% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 27/24/27 | 15.89 | -1.30% |
| 26/24/26 | 16.1 | +0.63% |
| 25/24/25 | 16 | -3.03% |
| 24/24/24 | 16.5 | -3.45% |
| 21/24/21 | 17.09 | +0.35% |
Real-time Boerse Frankfurt Warrants
Last update June 27, 2024 at 02:51 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC7ZJQ |
| ISIN | DE000PC7ZJQ7 |
| Date issued | 09/04/2024 |
| Strike | 1,000 $ |
| Maturity | 19/12/2025 (541 Days) |
| Parity | 10 : 1 |
| Emission price | 20.77 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 27.54 € |
|---|---|
| Lowest since issue | 15.54 € |
| Spread | 0.03 € |
| Spread % | 0.19% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
901.3
USD
Average target price
860.5
USD
Spread / Average Target
-4.52%
- Stock Market
- Warrants
- Warrant
